Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brivanib randomized discontinuation study in FGF-2 overexpressing advanced solid tumors
NL-OMON32125Phase 2Active, not recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Jan 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of brivanib in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC), gastric adenocarcinoma and 5 more (3 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Progression-free survival. Started Jan 2009; status: active, not recruiting.
02
Drugs
brivanib
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)gastric adenocarcinomaesophageal adenocarcinoma (EAC)soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NL-OMON32125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON32125.